
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is a leader in tech-enabled biotech and next-gen biologics space with a business model that is underappreciated by investors. Their AI/ML technology platform and integrated drug discovery strategy have the potential to become a >$5B market cap company in the longer-term. Key highlights include diversified partnerships, a strong computational platform, best-in-class AI/ML engines, and impressive growth in forging new partnerships. However, risks to the rating and price target include clinical risks and competition, as well as financial risks related to the need for additional funds and uncertainty around the success of existing partnerships.
Bears say
Absci is known for its ML/AI drug discovery space and its lead product candidate, ABS-201, which has shown potential dosing of 2-3 injections over a 6-month period, making it an attractive option in the hair growth market. While the recent investment from Lilly and safety data in clinical trials are promising, there are still risks that could prevent the stock from reaching its $16 price target, such as competition and dilution.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares